Tower Research Capital (TRC)’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Tower Research Capital (TRC)’s Portfolio RXII Stock Details RXII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-27,293	Closed	-$13K	–	5245
2016 Q2	$13K	Buy	+27,293	New	+$13K	﹤0.01%	2631
2016 Q1	–	Sell	-10,866	Closed	-$16K	–	5725
2015 Q4	$16K	Buy	+10,866	New	+$16K	﹤0.01%	1582
2015 Q2	–	Sell	-33,327	Closed	-$46K	–	5679
2015 Q1	$46K	Buy	+33,327	New	+$46K	0.01%	1551
2014 Q4	–	Sell	-21,897	Closed	-$45K	–	5493
2014 Q3	$45K	Buy	+21,897	New	+$45K	0.01%	1631
2014 Q2	–	Sell	-400	Closed	-$1K	–	5363
2014 Q1	$1K	Buy	+400	New	+$1K	﹤0.01%	4362
2013 Q4	–	Sell	-825	Closed	-$2K	–	5486
2013 Q3	$2K	Buy	+825	New	+$2K	﹤0.01%	4238

Other funds holding RXII

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Tower Research Capital (TRC)'s RXII Position: Q3 2016 in Review

Tower Research Capital (TRC) sold out of GALENA BIOPHARMA INC COM (RXII) in Q3 2016, closing a stake of 27,293 shares — an estimated $13K sold.

Tower Research Capital (TRC) first reported a position in RXII in Q3 2013 and held it in 6 quarters. The position peaked at $46K in Q1 2015. 92 funds tracked by Wall St. Rank hold RXII as of Q3 2016.

Tower Research Capital (TRC) reported no remaining GALENA BIOPHARMA INC COM position as of Q3 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 27,293 GALENA BIOPHARMA INC COM shares in Q3 2016, an estimated $13K.
Tower Research Capital (TRC) first reported a position in GALENA BIOPHARMA INC COM in Q3 2013 and held it in 6 quarters.
Tower Research Capital (TRC)'s GALENA BIOPHARMA INC COM position peaked at $46K in Q1 2015.
92 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q3 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2016, filed 8 Nov 2016.